[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362860-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362860-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","m2-macrophages-predict-response-to-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer-patients","M2 macrophages predict response to neoadjuvant chemotherapy in triple negative breast cancer patients","","M2 macrophages, a dominant immune-related stromal population in the tumor microenvironment, can be polarized and linked to immunosuppression. This study assessed whether CD163-positive M2 macrophage infiltration predicts response to neoadjuvant chemotherapy in triple negative breast cancer (TNBC). CD163 levels were measured on surgical specimens from 42 Chinese TNBC patients, alongside CD8-positive cytotoxic T cells and PD-L1 expression. Lower CD163-positive M2 infiltration aligned with higher pCR, and stromal CD163-positive M2 level was the strongest predictor.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/m2-macrophages-predict-response-to-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer-patients/362860/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/m2-macrophages-predict-response-to-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer-patients/362860.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What immune markers were evaluated to predict chemotherapy response in TNBC?","Question",{"text":63,"@type":64},"The study measured CD163-positive M2 macrophages, along with PD-L1 expression and CD8-positive cytotoxic T cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was response to neoadjuvant chemotherapy assessed?",{"text":68,"@type":64},"Response was evaluated using pathological complete response (pCR), defined as no residual invasive carcinoma.",{"name":70,"@type":61,"acceptedAnswer":71},"What relationship did stromal M2 macrophage infiltration have with pCR?",{"text":72,"@type":64},"Higher infiltration of CD163-positive M2 macrophages was negatively associated with chemotherapeutic response, and stromal CD163-positive M2 level was the strongest factor.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362860,1790182128,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nM2 macrophages predict response to neoadjuvant chemotherapy in triple negative breast cancer patients  \nWei-xian Chen1􀀍, Mei Yang1, Quan-feng Shao1, Bei Zhu1, Jiao Xue1, Lin Zheng1, Xi-hu Qin1 & Chun-jian Qi2􀀍  \nMacrophages, the predominant immune-related stromal cells within tumor microenvironment, could be polarized into M1 and alternative M2 macrophages. M1 macrophages are pro-inflammatory and eliminate cancer cells, whereas M2 macrophages are immunosuppressive and facilitate tumor growth. Mounting evidence has shown that M2 macrophages are responsible for a poor prognosis in triple negative breast cancer (TNBC) patients. Since neoadjuvant chemotherapy is becoming the foundation treatment forTNBC, the relationship between M2 macrophages and response to neoadjuvant chemotherapy remains to be elucidated. Infiltration of M2 macrophages were checked by analyzing the CD163 levels on surgical resection specimens from 42 Chinese TNBC patients treated with neoadjuvant chemotherapy. Evaluation of M2 macrophages together with other immune markers including CD8-positive cytotoxic T cells and PD-L1 expression inTNBC and its association with pCR after neoadjuvant chemotherapy were performed. Pathological complete response (pCR) was significantly associated with younger age, higher tumor or stromal PD-L1 expression, higher levels of tumor or stromal CD8-positive cytotoxic T cells, but lower infiltration of CD163-positive M2 macrophages, with the level of CD163-positive M2 macrophages in stromal area as the strongest factor. Our study showed that high infiltration of CD163-positive M2 macrophages was negatively associated with the chemotherapeutic response to neoadjuvant chemotherapy in Chinese TNBC patients and could be used as a promising prognostic candidate for Chinese TNBC patients treated with neoadjuvant chemotherapy.  \nKeywords Triple negative breast cancer (TNBC), M2 macrophages, PD-L1, Neoadjuvant chemotherapy, Tumor-infiltrating lymphocytes  \nBreast cancer is the most common malignancy among women worldwide, and the subtype of particular note is triple negative breast cancer (TNBC) which accounts for 10–20% of all breast cancers and is characterized by the lack of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor-2 (HER-2) expression1. Neoadjuvant chemotherapy is becoming the foundation treatment for TNBC patients2,3. Tumor response to neoadjuvant chemotherapy is commonly evaluated by microscopically checking the surgical resection specimens, and pathological complete response (pCR) is defined as no residual invasive carcinoma. Standard neoadjuvant strategy for TNBC includes regimens with cycles ofanthracycline and cyclophosphamide followed by cycles of taxanes (EC-T regimen)2,3. Accumulating studies have shown that the utility of neoadjuvant chemotherapy results in a significantly higher pCR rate in TNBC patients than in hormone receptor-positive breast cancer patients4.  \nNeoadjuvant chemotherapy could modify the tumor immune microenvironment in several ways5. Moreover, changes in tumor immunity after neoadjuvant chemotherapy were more common in TNBC with respect to other subtypes6. Macrophages, the most abundant immune-related stromal cells within tumor microenvironment, could be polarized into M1 and alternative M2 macrophages. M1 macrophages are proinflammatory and eliminate cancer cells, whereas M2 macrophages are immunosuppressive and facilitate tumor  \n1Department of Breast Surgery, Changzhou No. 2 People’s Hospital, The Third Affiliated Hospital of Nanjing Medical University, 468 Yanling Mid Road, Changzhou 213000, Jiangsu Province, China. 2Clinical Cancer Research Center, Changzhou No.2 People’s Hospital, The Third Affiliated Hospital of Nanjing Medical University, Changzhou 213000, Jiangsu Province, China. 􀀍 email: [chenweixian@njmu.edu.cn](chenweixian@njmu.edu.cn); [dhczey@163.com](dhczey@163.com)  \n[","cbCaibPS50RQRBmE","https://ap.wps.com/l/cbCaibPS50RQRBmE","pdf",1426604,"English","# Methods\n## Patients and samples","[{\"question\":\"What immune markers were evaluated to predict chemotherapy response in TNBC?\",\"answer\":\"The study measured CD163-positive M2 macrophages, along with PD-L1 expression and CD8-positive cytotoxic T cells.\"},{\"question\":\"How was response to neoadjuvant chemotherapy assessed?\",\"answer\":\"Response was evaluated using pathological complete response (pCR), defined as no residual invasive carcinoma.\"},{\"question\":\"What relationship did stromal M2 macrophage infiltration have with pCR?\",\"answer\":\"Higher infiltration of CD163-positive M2 macrophages was negatively associated with chemotherapeutic response, and stromal CD163-positive M2 level was the strongest factor.\"}]","M2 macrophages predict response to neoadjuvant chemotherapy in triple negative breast cancer patients | PDF",1790149253,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/703085c4a487b3f2cbb0b9d494ff8397.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2be748d8979e97df58e01e66bccdd715.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35f03b5dd2dfae5518b980f8e1e892dc.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e07a671f84e0aec9850edad21f8ad6fd.webp",980,1287]